Feasible study of the effect of irbesartan on psoriasis

Feasible study of the effect of irbesartan on psoriasis - The effect of irbesartan on psoriasis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000025949

Enrollment

Registered

2017-02-01

Start date

2012-10-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

psoriasis

Interventions

Administration period is three months. Dosage of irbesartan is 100mg.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Psoriasis patients with hypertension

Exclusion criteria

Exclusion criteria: Minors or adults of imcomplete judgement

Design outcomes

Primary

Measure	Time frame
Assessment of PASI three months after the start of Irbesartan	—

Secondary

Measure	Time frame
Assessment of PDI three months after the start of Irbesartan	—

Countries

Japan

Contacts

Public ContactHideki Nakajima

Kochi Medical School Department of Dermatology

nakajima@kochi-u.ac.jp0888802363

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026